- Home
- DOUG vs CMPX Comparison
DOUG vs CMPX Comparison
Compare DOUG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- CMPX
- Stock Information
- Founded
- DOUG 1911
- CMPX 2014
- Country
- DOUG United States
- CMPX United States
- Employees
- DOUG N/A
- CMPX N/A
- Industry
- DOUG Building operators
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- CMPX Health Care
- Exchange
- DOUG Nasdaq
- CMPX Nasdaq
- Market Cap
- DOUG 142.2M
- CMPX 214.6M
- IPO Year
- DOUG N/A
- CMPX N/A
- Fundamental
- Price
- DOUG $1.58
- CMPX $2.00
- Analyst Decision
- DOUG
- CMPX Strong Buy
- Analyst Count
- DOUG 0
- CMPX 4
- Target Price
- DOUG N/A
- CMPX $13.75
- AVG Volume (30 Days)
- DOUG 1.0M
- CMPX 1.8M
- Earning Date
- DOUG 02-27-2025
- CMPX 11-12-2024
- Dividend Yield
- DOUG N/A
- CMPX N/A
- EPS Growth
- DOUG N/A
- CMPX N/A
- EPS
- DOUG N/A
- CMPX N/A
- Revenue
- DOUG $966,442,000.00
- CMPX $850,000.00
- Revenue This Year
- DOUG $5.28
- CMPX N/A
- Revenue Next Year
- DOUG $16.40
- CMPX $613.39
- P/E Ratio
- DOUG N/A
- CMPX N/A
- Revenue Growth
- DOUG 1.86
- CMPX N/A
- 52 Week Low
- DOUG $1.00
- CMPX $0.77
- 52 Week High
- DOUG $2.98
- CMPX $2.68
- Technical
- Relative Strength Index (RSI)
- DOUG 38.30
- CMPX 65.48
- Support Level
- DOUG $1.49
- CMPX $1.43
- Resistance Level
- DOUG $1.84
- CMPX $2.68
- Average True Range (ATR)
- DOUG 0.12
- CMPX 0.24
- MACD
- DOUG 0.00
- CMPX 0.06
- Stochastic Oscillator
- DOUG 25.79
- CMPX 46.87
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.